Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan Gu

Showing results (1071-1080 of 1,076) with videos related to

Pageof 108
Sort By:
You have reached the last page of results.This site can display upto 1,076 results.
Bioorganic & Medicinal Chemistry Letters|March 19, 2011
Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitorsJohn L Buchanan, John R Newcomb, David P Carney, et al.
ERJ Open Research|February 27, 2024
A phase 4 multicentre, 2×2 factorial randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of tobramycin inhalation solution for <i>Pseudomonas aeruginosa</i> eradication in bronchiectasis: ERASEYong-Hua Gao, Hai-Wen Lu, Hui-Zhen Zheng, et al.
The Lancet. Respiratory Medicine|January 13, 2025
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort studyJin-Fu Xu, Hui-Zhen Zheng, Hai-Wen Lu, et al.
Journal of Medicinal Chemistry|March 7, 2008
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activationErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|September 15, 2006
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activityErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|August 4, 2006
Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activityMatthew W Martin, John Newcomb, Joseph J Nunes, et al.
Pageof 108

Showing results (1071-1080 of 1,076) with videos related to

Sort By:
Pageof 108
You have reached the last page of results.This site can display upto 1,076 results.
Bioorganic & Medicinal Chemistry Letters|March 19, 2011
Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitorsJohn L Buchanan, John R Newcomb, David P Carney, et al.
ERJ Open Research|February 27, 2024
A phase 4 multicentre, 2×2 factorial randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of tobramycin inhalation solution for <i>Pseudomonas aeruginosa</i> eradication in bronchiectasis: ERASEYong-Hua Gao, Hai-Wen Lu, Hui-Zhen Zheng, et al.
The Lancet. Respiratory Medicine|January 13, 2025
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort studyJin-Fu Xu, Hui-Zhen Zheng, Hai-Wen Lu, et al.
Journal of Medicinal Chemistry|March 7, 2008
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activationErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|September 15, 2006
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activityErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|August 4, 2006
Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activityMatthew W Martin, John Newcomb, Joseph J Nunes, et al.
Pageof 108